Maridebart Cafraglutide
Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations After Multiple Doses
Amgen · Phase 1 · Not yet recruiting · Enrollment 356
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Maridebart Cafraglutide: SC Presentation 1 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Maridebart Cafraglutide: SC Presentation 2 | Obesity or overweight | n/r | n/r | n/r | n/r |